Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Maria Teresa VOSO

Professore Ordinario di Ematologia

Università degli Studi di Roma Tor Vergata Facoltà di Medicina e Chirurgia

Italy

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Immunology

30%

Cell Biology

30%

Hematology

50%

Hematopoiesis

30%

Graft-versus-host Disease

30%

Oncology

30%

Epithelial-mesenchymal Transition

20%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles17

Unmet Needs and Their Impact on Quality of Life and Symptoms in Myelodysplastic Neoplasm Patients and Caregivers

Article Link

Year:

2025

Acute promyelocytic leukemia: long-term outcomes from the HARMONY project

Article Link

Year:

2025

Microenvironment in acute myeloid leukemia: focus on senescence mechanisms, therapeutic interactions, and future directions

Article Link

Year:

2024

Financial Toxicity and Health-Related Quality of Life Profile of Patients With Hematologic Malignancies Treated in a Universal Health Care System

Article Link

Year:

2024

Acute Promyelocytic Leukemia-like AML: Genetic Perspective and Clinical Implications

Article Link

Year:

2024

Combination Treatment of Resistant Acute Promyelocytic Leukemia Cells with Arsenic Trioxide and Anti-Apoptotic Gene Inhibitors

Article Link

Year:

2024

Response Rates and Transplantation Impact in Patients with Relapsed Acute Promyelocytic Leukemia

Article Link

Year:

2024

YY1 Knockdown Relieves the Differentiation Block and Restores Apoptosis in AML Cells

Article Link

Year:

2023

Acute Myeloid Leukemia with NPM1 Mutation and Disseminated Leukemia Cutis: Achievement of Molecular Complete Remission by Venetoclax/Azacitidine Combination in a Very Old Patient

Article Link

Year:

2023

Outcome prediction in myelodysplastic neoplasm undergoing hematopoietic cell transplant in the molecular era of IPSS-M

Article Link

Year:

2023

LGL Clonal Expansion and Unexplained Cytopenia: Two Clues Don’t Make an Evidence

Article Link

Year:

2022

AML: making residual disease more measurable

Article Link

Year:

2022

Clonal haematopoiesis as a risk factor for therapy‐related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo‐(immuno)therapy

Article Link

Year:

2022

Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol

Article Link

Year:

2022

Ascorbate Plus Buformin in AML: A Metabolic Targeted Treatment

Article Link

Year:

2022

Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status

Article Link

Year:

2022

Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results

Article Link

Year:

2022

Collaborators11

daniela cilloni

PROFESSOR

University of Turin

ITALY

Jesús María Hernández-Rivas

Universidad de Salamanca

SPAIN

GIORGIA SIMONETTI

IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori

ITALY

Emiliano FABIANI

Professor of Technical Sciences of Laboratory Medicine in Medicine and Surgery Degree

Saint Camillus International University of Health Sciences

ITALY

Renato Zambello

ITALY

Francesco Buccisano

Associate Professor

UNIVERSITY TOR VERGATA

ITALY

Francesco Albano

ITALY

Gianluca GAIDANO

Professor of Hematology

ITALY

Clara NERVI

ITALY

Simona Pagliuca

FRANCE

Maria Paola Martelli

ITALY

How do I reach out?

Meet Kite AI